Trial · NCT06036914

A Study of Ultra High Dose Diuretics to Treat Heart Failure

NCT06036914, Phase 2, Completed, Mayo Clinic; results first posted 2026-01-14

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of Ultra High Dose Diuretics to Treat Heart Failure. Trials, record NCT06036914. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06036914

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of Ultra High Dose Diuretics to Treat Heart Failure
NCT number: NCT06036914
Status: Completed
Phases: Phase 2
Enrollment: 20 participants, actual
Lead sponsor: Mayo Clinic
Conditions: Heart Failure; With Decompensation
Interventions: Bumetanide, Furosemide
First posted: 2023-09-14
Last updated: 2026-01-14
Results first posted: 2026-01-14

Source ClinicalTrials.gov

Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Urine Output	24 hours	The total volume of urine produced in milliliters (mL) over 24 hours after initiation of intravenous diuretic.
Secondary	Change in Body Weight	Baseline, 24 hours	Change in Body Weight (kg) from Baseline to 24 hours after initiation of intravenous diuretic.
Secondary	Change in NT-proBNP	Baseline, 24 hours	Change in NT-proBNP levels (pg/ml) from Baseline to 24 hours after initiation of intravenous diuretic.
Secondary	Change in Urine Sodium Excretion	Baseline, 24 hours	Change in amount of sodium (mmol) excreted in the urine from Baseline to 24 hours after initiation of intravenous diuretic.
Secondary	Change in Apnea-hypopnea Index	Baseline, 24 hours	The apnea-hypopnea index (AHI) is the number of apneas and hypopneas per hour of sleep which is an indicator of severity of sleep apnea AHI will be measured using a Watch Pat or Nox device at Baseline and 24 hours after initiation of intravenous diuretic.
Secondary	Change in Iohexol Glomerular Filtration Rate (GFR)	Baseline, 24 hours	Renal or kidney function was measured by GFR determined by Iohexol clearance. Iohexol GFR will be measured at Baseline and 24 hours after initiation of intravenous diuretic.
Secondary	Change in Peripheral Vein Pressure	Baseline, 24 hours	Peripheral vein pressure (mm Hg) will be recorded from existing IV lines through pressure transducer monitoring at Baseline and 24 hours after initiation of intravenous diuretic.
Secondary	Change in Cardiac Output	Baseline, 24 hours	Cardiac output (L/min) is the total volume of blood moved by the heart per minute and will be measured by echocardiography conducted at Baseline and 24 hours after initiation of intravenous diuretic.
Secondary	Change in Estimated Right Ventricular (RV) Systolic Pressure	Baseline, 24 hours	Estimated RV systolic pressure (mm Hg) will be measured by echocardiography conducted at Baseline and 24 hours after initiation of intravenous diuretic.
Secondary	Change in Right Atrial (RA) Pressure	Baseline, 24 hours	RA pressure (mm Hg) will be measured by echocardiography conducted at Baseline and 24 hours after initiation of intravenous diuretic.

1 to 10 of 14Source ClinicalTrials.gov

See all 14 registered outcomes

Outcomes14

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Urine Output	24 hours		mL	MEAN
SECONDARY	Change in Body Weight	Baseline, 24 hours		kg	MEAN
SECONDARY	Change in NT-proBNP	Baseline, 24 hours		pg/ml	MEAN
SECONDARY	Change in Urine Sodium Excretion	Baseline, 24 hours	Data for this outcome measure was not collected for any participants. Upon study initiation, this outcome measure was not technically feasible to obtain with existing staffing and was therefore not performed. As a results, no data was collected for this outcome measure.
SECONDARY	Change in Apnea-hypopnea Index	Baseline, 24 hours	Data for this outcome measure was not collected for any participants. Upon study initiation, this outcome measure was not technically feasible to obtain with existing staffing and was therefore not performed. As a result, no data was collected for this outcome measure.
SECONDARY	Change in Iohexol Glomerular Filtration Rate (GFR)	Baseline, 24 hours	Data for this outcome measure was not collected for any participants. Upon study initiation, this outcome measure was not technically feasible to obtain with existing staffing and was therefore not performed. As a result, no data was collected for this outcome measure.
SECONDARY	Change in Peripheral Vein Pressure	Baseline, 24 hours	Data was not collected for 1 subject in the Ultra-High dose diuretic group as the subject requested that peripheral vein pressure data not be collected on them.	mmHg	MEAN
SECONDARY	Change in Cardiac Output	Baseline, 24 hours	Data was not technically feasible to obtain for 3 subjects in the Ultra-High Dose diuretic group for this outcome measure.	L/min	MEAN
SECONDARY	Change in Estimated Right Ventricular (RV) Systolic Pressure	Baseline, 24 hours	Data for this outcome measure was not collected for any participants. Upon study initiation, this outcome measure was not technically feasible to obtain with existing staffing and was therefore not performed. As a result, no data was collected for this outcome measure.
SECONDARY	Change in Right Atrial (RA) Pressure	Baseline, 24 hours	Data for this outcome measure was not collected for any participants. Upon study initiation, this outcome measure was not technically feasible to obtain with existing staffing and was therefore not performed. As a result, no data was collected for this outcome measure.

1 to 10 of 14Source ClinicalTrials.gov

See all 14 outcomes

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Urine Output	Ultra-high Dose Diuretic Group	5283	Standard Deviation 2976	mL
Urine Output	Standard Dose Diuretic Group	2819	Standard Deviation 1060	mL
Change in Body Weight	Ultra-high Dose Diuretic Group	-2.6	Standard Deviation 3.0	kg
Change in Body Weight	Standard Dose Diuretic Group	-3.8	Standard Deviation 3.3	kg
Change in NT-proBNP	Ultra-high Dose Diuretic Group	2898	Standard Deviation 7278	pg/ml
Change in NT-proBNP	Standard Dose Diuretic Group	-1705	Standard Deviation 1712	pg/ml
Change in Peripheral Vein Pressure	Ultra-high Dose Diuretic Group	-10.9	Standard Deviation 7.5	mmHg
Change in Peripheral Vein Pressure	Standard Dose Diuretic Group	-4	Standard Deviation 3.1	mmHg
Change in Cardiac Output	Ultra-high Dose Diuretic Group	-0.53	Standard Deviation 0.83	L/min
Change in Cardiac Output	Standard Dose Diuretic Group	0.29	Standard Deviation 1.50	L/min

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ultra-high Dose Diuretic Group	10
Overall Study	STARTED	Standard Dose Diuretic Group	10
Overall Study	COMPLETED	Ultra-high Dose Diuretic Group	9
Overall Study	COMPLETED	Standard Dose Diuretic Group	10
Overall Study	NOT COMPLETED	Ultra-high Dose Diuretic Group	1
Overall Study	NOT COMPLETED	Standard Dose Diuretic Group	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Ultra-high Dose Diuretic Group	10
Total, all-cause mortality	Standard Dose Diuretic Group	10
Total, other adverse events	Ultra-high Dose Diuretic Group	10
Total, other adverse events	Standard Dose Diuretic Group	10
Total, serious adverse events	Ultra-high Dose Diuretic Group	10
Total, serious adverse events	Standard Dose Diuretic Group	10

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Ultra-high Dose Diuretic Group vs Standard Dose Diuretic Group: deaths from any cause	Trial comparisons
Ultra-high Dose Diuretic Group vs Standard Dose Diuretic Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06036914

GET https://conductscience.org/api/trials/v1/NCT06036914/registered

API reference For AI assistants